270 related articles for article (PubMed ID: 2968759)
1. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
Borgmann V; al-Abadi H; Nagel R
Am J Clin Oncol; 1988; 11 Suppl 1():S19-28. PubMed ID: 2968759
[TBL] [Abstract][Full Text] [Related]
2. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
Debruyne FM
Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
[TBL] [Abstract][Full Text] [Related]
3. [1st clinical results of the treatment of locally advanced prostatic cancer with a powerful LH-RH analog: buserelin acetate].
Nagel R; Borgmann V; Al-Abadi H; Schmidt-Gollwitzer M
J Urol (Paris); 1983; 89(9):669-76. PubMed ID: 6425419
[TBL] [Abstract][Full Text] [Related]
4. The prognostic significance of ploidy and DNA-heterogeneity in the primary diagnosis and monitoring of patients with locally advanced prostatic carcinoma.
Nagel R; al Abadi H
Scand J Urol Nephrol Suppl; 1991; 138():83-92. PubMed ID: 1785025
[TBL] [Abstract][Full Text] [Related]
5. Endocrine and clinical evaluation of 107 patients with advanced prostatic carcinoma under long-term pernasal buserelin or intramuscular decapeptyl depot treatment.
Jacobi GH; Wenderoth UK; Ehrenthal W; von Wallenberg H; Spindler HW; Hohenfellner R
Am J Clin Oncol; 1988; 11 Suppl 1():S36-43. PubMed ID: 2968761
[TBL] [Abstract][Full Text] [Related]
6. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
[TBL] [Abstract][Full Text] [Related]
7. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
Oosterlinck W; Mattelaer J; Casselman J; Van Velthoven R; Derde MP; Kaufman L
Acta Urol Belg; 1997 Oct; 65(3):63-71. PubMed ID: 9421938
[TBL] [Abstract][Full Text] [Related]
8. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
Moreau JP; Delavault P; Blumberg J
Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
[TBL] [Abstract][Full Text] [Related]
9. Use of gonadotropin-releasing hormone analogue in advanced prostatic cancer: 3 years clinical experience.
Matzkin H; Greenstein A; Kaver I; Braf Z
Isr J Med Sci; 1989 Jul; 25(7):388-92. PubMed ID: 2474522
[TBL] [Abstract][Full Text] [Related]
10. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
Pettersson B; Varenhorst E; Petas A; Sandow J
Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study.
Ueno S; Namiki M; Fukagai T; Ehara H; Usami M; Akaza H
Int J Urol; 2006 Dec; 13(12):1494-500. PubMed ID: 17118024
[TBL] [Abstract][Full Text] [Related]
12. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
Labrie F; Dupont A; Belanger A; Cusan L; Lacourciere Y; Monfette G; Laberge JG; Emond JP; Fazekas AT; Raynaud JP; Husson JM
Clin Invest Med; 1982; 5(4):267-75. PubMed ID: 6819101
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
[TBL] [Abstract][Full Text] [Related]
14. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
15. [Therapy of prostatic cancer with cyproterone acetate].
Maier U
Wien Klin Wochenschr; 1988 Jan; 100(1):16-9. PubMed ID: 2964127
[TBL] [Abstract][Full Text] [Related]
16. Treatment of prostatic cancer with LH-RH analogues.
Borgmann V; Nagel R; Al-Abadi H; Schmidt-Gollwitzer M
Prostate; 1983; 4(6):553-68. PubMed ID: 6415628
[TBL] [Abstract][Full Text] [Related]
17. [Clinical studies in prostatic carcinoma].
Kumanov Kh; Tsvetkov M
Khirurgiia (Sofiia); 1993; 46(5):6-8. PubMed ID: 7983831
[TBL] [Abstract][Full Text] [Related]
18. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
19. A long term follow-up of patients with advanced prostatic cancer treated with buserelin.
Waxman JH; Hendry WF; Whitfield HN; Oliver RT
Prog Clin Biol Res; 1985; 185A():271-7. PubMed ID: 3929266
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
Stege R; Grande M; Carlström K; Tribukait B; Pousette A
Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]